MIRA Pharmaceuticals, Inc. announced positive preclinical study results for MIRA-55, its non-opioid oral drug candidate for chronic inflammatory pain. The optimized oral formulation demonstrated favorable oral bioavailability, sustained systemic exposure, and reproducible distribution into brain and liver tissue. MIRA Pharmaceuticals, Inc. is a pharmaceutical company developing non-opioid pain management therapies.
